Spyre Posts $96.1M Q3 Loss, Expands HS Program With $1.5B Pro Forma Cash
SYRE has more than doubled off its 52-week low of $21.145.
Summary
Spyre's Q3 net loss widened to $96.1 million from $11.2 million a year ago as R&D spending nearly doubled to $89.2 million on manufacturing and trial costs. The company ended September with $1,071.9 million in cash and securities, and $1,467.9 million pro forma for the October offering and ATM sales, funding operations into the second half of 2029. On the pipeline, SPY072 missed its primary endpoints in the PsA and axSpA sub-studies and will not advance in rheumatic disease, but Spyre is redirecting the TL1A asset into a new Phase 2 SKYLIGHT trial in hidradenitis suppurativa, backed by the $400 million-plus October raise. SKYLINE Part B is enrolling ahead of schedule, letting Spyre raise the enrollment target for three combination arms with induction data now expected in Q3 2027. The cash position removes near-term financing risk; the read is mixed on data, with the rheumatic disease failure offset by the HS pivot and faster IBD combination enrollment.
At the time of this announcement, SYRE was trading at $99.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.2B. The 52-week trading range was $21.15 to $110.18. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.